donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
KNSA Kiniksa Pharmaceuticals
10.120
+0.430+4.44%
Post Mkt Price
10.12000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-- 230.3049 -- 137.5903 -- 137.5903 -- --
Receivable Turnover(T)
-- 2.4026 -- 9.6723 -- 9.6723 -- 6.1411
Inventory Turnover(T)
-- 2.7995 -- 2.4762 -- 2.4762 -- --
Fixed Assets Turnover(T)
-- 8.2792 -- 4.0571 -- 4.0571 -- 2.6337
Total Asset Rate(T)
-- 0.2609 -- 0.1324 -- 0.1324 -- 0.0621
ROIC
21.73% -59.575% -4.47% -61.958% -4.47% -61.958% -31.48% -60.355%
ROE
20.97% -61.175% -5.81% -63.555% -5.81% -63.555% -33.91% -61.216%
ROA
28.19% -49.306% -1.51% -54.245% -1.51% -54.245% -31.31% -54.999%
Efficiency Ratios
ROA 5 Year Average
-- -- -3.54% -68.905% -- -- -- --
Profitability Ratios TTM
Gross Margin
-- 69.501% -- 76.391% -- 76.391% -- --
Operating Margin
-- -184.740% -- -406.382% -- -406.382% -- -875.817%
Net Margin
-- -188.950% -- -409.724% -- -409.724% -- -885.136%
EBITDA Margin
-- -1.8092% -- -4.0027% -- -4.0027% -- -8.6443%
R & D Expense Ratio
-- 129.260% -- 257.620% -- 257.620% -- 551.860%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-18.74% 1.261% -7.76% 1.442% -7.76% 1.442% 10584.31% 1.635%
Total Assets to Common Equity
20.87% 138.931% 12.3% 125.813% 12.3% 125.813% 10.17% 118.132%
Debt to Asset Ratio
33.92% 3.252% 46.02% 3.270% 46.02% 3.270% 630.29% 3.151%
Current Ratio
-49.22% 3.9472 -58.12% 4.3826 -58.12% 4.3826 -58.44% 6.3181
Quick Ratio
-53.33% 3.4757 -59.11% 4.1537 -59.11% 4.1537 -59.64% 5.9084
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
CEO: Patel, Sanj K.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...